Bionomics Valuation

Is B1N0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of B1N0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate B1N0's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate B1N0's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for B1N0?

Other financial metrics that can be useful for relative valuation.

B1N0 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does B1N0's PB Ratio compare to its peers?

The above table shows the PB ratio for B1N0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average4.9x
T5O bioXXmed
14.3xn/a€1.4m
CNW co.don
1xn/a€6.5m
MDG1 Medigene
1.3x-4.1%€24.1m
HPHA Heidelberg Pharma
3.1x-33.0%€118.4m
B1N0 Bionomics
0.3xn/a€8.5m

Price-To-Book vs Peers: B1N0 is good value based on its Price-To-Book Ratio (0.3x) compared to the peer average (5.8x).


Price to Earnings Ratio vs Industry

How does B1N0's PE Ratio compare vs other companies in the DE Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a36.2%
n/an/an/a
No. of CompaniesPB048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a36.2%
n/an/an/a
No more companies

Price-To-Book vs Industry: B1N0 is good value based on its Price-To-Book Ratio (0.3x) compared to the European Biotechs industry average (2.5x).


Price to Book Ratio vs Fair Ratio

What is B1N0's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

B1N0 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate B1N0's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst B1N0 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.25
€9.28
+3,582.4%
59.2%€16.75€3.70n/a3
Oct ’25€0.38
€9.28
+2,354.9%
59.2%€16.75€3.70n/a3
Sep ’25€0.56
€9.28
+1,542.4%
59.2%€16.75€3.70n/a3
Aug ’25€0.73
€9.28
+1,171.2%
59.2%€16.75€3.70n/a3
Jul ’25n/a
€9.37
0%
59.5%€16.97€3.77n/a3
Jun ’25€0.86
€9.21
+971.2%
59.0%€16.61€3.69n/a3
May ’25n/a
€9.21
0%
59.0%€16.61€3.69n/a3
Apr ’25€0.91
€9.21
+917.9%
59.0%€16.61€3.69n/a3
Mar ’25€1.40
€10.45
+646.7%
29.3%€14.61€7.33n/a3
Feb ’25€0.86
€10.45
+1,108.5%
29.3%€14.61€7.33n/a3
Jan ’25€1.45
€11.00
+658.3%
33.3%€16.03€7.42n/a3
Dec ’24€1.29
€10.90
+744.7%
32.1%€15.74€7.58n/a3
Nov ’24€2.54
€10.90
+329.0%
32.1%€15.74€7.58€0.163
Oct ’24€2.82
€11.01
+290.3%
32.5%€15.94€7.59€0.383
Sep ’24€1.90
€10.70
+463.0%
43.1%€15.30€6.09€0.562
Aug ’24€1.91
€10.41
+445.1%
40.4%€14.62€6.21€0.732
Jul ’24n/a
€8.85
0%
47.1%€14.73€5.56n/a3
Jun ’24n/a
€9.10
0%
42.9%€14.51€5.48€0.863
May ’24n/a
€9.10
0%
42.9%€14.51€5.48n/a3
Apr ’24€2.18
€8.97
+311.3%
32.4%€13.44€5.60€0.914
Mar ’24n/a
€11.37
0%
35.8%€16.29€5.75€1.404
Feb ’24n/a
€11.54
0%
35.6%€16.49€5.82€0.864
Jan ’24n/a
€11.39
0%
36.1%€16.00€5.65€1.454
Dec ’23n/a
€31.11
0%
48.9%€55.87€15.91€1.295
Nov ’23n/a
€32.63
0%
43.7%€55.85€15.90€2.545

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies